Literature DB >> 34012364

Luminal Metastatic Breast Cancer: Current Concepts and Future Approaches.

Johannes Ettl1.   

Abstract

Entities:  

Year:  2021        PMID: 34012364      PMCID: PMC8114081          DOI: 10.1159/000515804

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  3 in total

1.  Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer.

Authors:  Kokoro Kobayashi; Yoshinori Ito; Masaaki Matsuura; Ippei Fukada; Rie Horii; Shunji Takahashi; Futoshi Akiyama; Takuji Iwase; Yasuo Hozumi; Yoshikazu Yasuda; Kiyohiko Hatake
Journal:  Surg Today       Date:  2015-10-14       Impact factor: 2.549

2.  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; PierFranco Conte; Yi Lu; Susana Barriga; Karla Hurt; Martin Frenzel; Stephen Johnston; Antonio Llombart-Cussac
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

3.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).

Authors:  F Cardoso; S Paluch-Shimon; E Senkus; G Curigliano; M S Aapro; F André; C H Barrios; J Bergh; G S Bhattacharyya; L Biganzoli; F Boyle; M-J Cardoso; L A Carey; J Cortés; N S El Saghir; M Elzayat; A Eniu; L Fallowfield; P A Francis; K Gelmon; J Gligorov; R Haidinger; N Harbeck; X Hu; B Kaufman; R Kaur; B E Kiely; S-B Kim; N U Lin; S A Mertz; S Neciosup; B V Offersen; S Ohno; O Pagani; A Prat; F Penault-Llorca; H S Rugo; G W Sledge; C Thomssen; D A Vorobiof; T Wiseman; B Xu; L Norton; A Costa; E P Winer
Journal:  Ann Oncol       Date:  2020-09-23       Impact factor: 32.976

  3 in total
  1 in total

1.  BTG2 as a tumor target for the treatment of luminal A breast cancer.

Authors:  Runzhi Wang; Ronghua Wang; Jinjun Tian; Jian Wang; Huaxiao Tang; Tao Wu; Hui Wang
Journal:  Exp Ther Med       Date:  2022-03-21       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.